A 25-year-old man, 3 years postmigration from India, was referred to our hospital with right apical nodular opacities on chest radiograph performed during routine migrant screening, which were presumed to be attributable to TB. He was asymptomatic, with no cough, dyspnea, fevers, night sweats, or recent weight loss. The patient had no remarkable medical history and did not take medications regularly. He reported no smoking or recreational drug use. He had no history of immune deficits such as HIV infection, malignancy, stem cell or solid organ transplant, steroid or other immunosuppressive drug use, diabetes mellitus, alcoholism, renal failure, liver failure, or previous splenectomy. He worked in manufacturing and had exposure to diesel engines and reported no exposure to soil, animals, or wastewater.

At initial assessment, the patient was afebrile and had no focal respiratory signs. Initial blood testing results were unremarkable; C-reactive protein and leukocyte counts were within reference ranges. Results of assay tests for TB and HIV were negative. Sputum specimens collected on 3 consecutive days were smear-negative for acid-fast bacilli (AFB) with auramine-rhodamine stain.

Figure

Figure. Computed tomography (CT) scans for reported case of Tsukamurella tyrosinosolvensinfection in 25-year-old immunocompetent man. A) Initial CT showing 25-mm cavitating right apical lesion. B) Repeat CT after 6...

Computed tomography (CT) of the chest showed variable-sized pulmonary nodules in the right lung apex and surrounding tree-in-bud changes (Figure). CT also identified 2 cavities; the larger cavity measured 25 mm and contained an air-fluid level. The remaining lung was clear. Cultures of all 3 sputum samples indicated Tsukamurella spp. most closely related to T. tyrosinosolvens. We performed species identification through targeted Sanger DNA sequencing of a 550-bp fragment of the 16S rRNA gene, followed by BLAST analysis (https://blast.ncbi.nlm.nih.gov) to determine the most closely matched species. Given radiologic findings consistent with active infection and repeated isolation of Tsukamurella spp., we decided to treat empirically with ciprofloxacin and clarithromycin (both 500 mg 2/d).

Subsequent sensitivity testing through broth microdilution demonstrated susceptibility to a broad range of antimicrobial drugs, intermediate susceptibility to doxycycline, and resistance to amoxicillin/clavulanic acid and tobramycin (Table). Given the lack of clinical data to support development of validated MIC breakpoints for Tsukamurella spp., we interpreted susceptibilities by using MIC breakpoints for Nocardia spp. by Clinical and Laboratory Standards Institute guidelines (14). Two further sputum samples collected 1 month later also were AFB smear-negative; however, we cultured Mycobacterium fortuitum from a single specimen, which was not considered causative or otherwise clinically important.

After 3 months of treatment, the patient remained asymptomatic and reported no adverse events associated with treatment. Repeat CT showed interval reduction of the cavitating lesion from 25 to 17 mm (Figure). Treatment was continued for another 3 months, at which time the nodules had further reduced in size; the cavitating lesion measured 10 mm (Figure). After 6 months of macrolide and fluoroquinolone therapy, treatment was stopped. We noted no radiologic signs of infection recurrence on repeat CT at 6 months after treatment cessation.

We describe a case of T. tyrosinosolvens infection as a cause of cavitating respiratory disease in an immunocompetent and otherwise healthy young man. This case challenges the characterization of Tsukamurella spp. as opportunistic pathogens and should raise awareness of Tsukamurella respiratory infection. Although Tsukamurella pulmonary infection is rare, the number of reports is increasing, and most cases have been published within the last decade (Appendix). The emergence of Tsukamurella bacteria as a cause of human infection probably reflects advances in laboratory methods and increased recognition of a previously misdiagnosed disease. Although the true prevalence remains unclear, epidemiologic studies in China indicated that 1% of presumed nontuberculous Mycobacteria respiratory samples were Tsukamurella spp. when they were retrospectively analyzed using molecular methods (15).

Underrecognition occurs for several reasons. Lack of awareness among clinicians and the practice of treating AFB culture-positive infection as presumed TB in some clinical settings contribute to misdiagnosis (2,7). Because Tsukamurella spp. respiratory infection might be clinically, radiologically, and morphologically indistinguishable from pulmonary TB and might also respond to treatment with first-line TB therapy, the risk for misdiagnosis is high in the absence of microbiologic confirmation. A broader differential including other aerobic actinomycetes could be beneficial, especially in patients not responding to initial therapy. Tsukamurella resistance to first-line TB treatment agents has been described (2). Misdiagnosis has been shown to lead to excess disease and death in some case reports (7), and can lead to use of unnecessary, toxicity-prone TB treatment regimens.

Microbiologic diagnosis often is resource-intensive. Standard laboratory phenotypic and biochemical methods might be inadequate to distinguish Tsukamurella from other aerobic actinomycetes. The advent of MALDI-TOF mass spectrometry and molecular techniques such as 16S rRNA and DNA sequencing have enabled accurate identification of Tsukamurella genus (2). Although 16S sequencing is an effective technique for identifying Tsukamurella genus, it often is insufficient to achieve species-level identification because of the high genetic conservation between species and lack of sequences available on public databases for comparison. Sequencing of additional housekeeping genes (e.g., groEL, secA, and rpoB) might be necessary for Tsukamurella species identification. Although some literature describes low diagnostic accuracy of Tsukamurella spp. with MALDI-TOF mass spectrometry, recent database improvements have demonstrated species-level identification with 98% accuracy (3). Therefore MALDI-TOF mass spectrometry might be an efficacious and cost-effective diagnostic method compared with DNA and RNA sequencing techniques. Unfortunately, those methods might not be routinely available outside metropolitan clinical microbiology and reference laboratories and can be impractical in settings with high TB prevalence.

Even once diagnosis is made, evidence to guide antibiotic choice and duration of therapy is scarce. Empiric regimens are based on previous case reports, and duration must be guided by clinical response. In the absence of validated MIC breakpoints, correlation between in vivo and in vitro sensitivities might be poor. Current Clinical and Laboratory Standards Institute guidelines provide tentative breakpoints for interpreting Tsukamurella spp. susceptibility testing on the basis of Nocardia spp. breakpoints (14); however, patients should be monitored to ensure appropriate clinical response.